keyword
MENU ▼
Read by QxMD icon Read
search

coinfection hiv hcv

keyword
https://www.readbyqxmd.com/read/28343937/co-infection-of-blood-borne-viruses-in-blood-donors-a-cross-sectional-study-from-north-india
#1
Ravi C Dara, Aseem K Tiwari, Dinesh Arora, Geet Aggarwal, Ganesh Singh Rawat, Jyoti Sharma, Devi Prasad Acharya, Gunjan Bhardwaj
BACKGROUND: There are several studies on prevalence of individual infectious disease markers (mono-infection) in donors but none on prevalence of coinfection. Co-infection is significant as it leads to accelerated disease progression. We, therefore, evaluated the prevalence of co-infection among blood donors. MATERIALS AND METHODS: The cross-sectional analysis was conducted in blood donors. All donors were tested for anti-HIV I and II, HBsAg, anti-HBC IgM, anti-HCV, Malaria and syphilis by chemiluminescence and ID-NAT assay...
March 6, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28340504/improving-the-outcomes-of-hiv-hcv-coinfected-transplant-recipients-the-answer-is-blowin-in-the-wind
#2
EDITORIAL
Ghady Haidar, Nina Singh
No abstract text is available yet for this article.
March 24, 2017: Liver Transplantation
https://www.readbyqxmd.com/read/28336560/lipoprotein-a-and-hiv-allele-specific-apolipoprotein-a-levels-predict-carotid-intima-media-thickness-in-hiv-infected-young-women-in-the-women-s-interagency-hiv-study
#3
Enkhmaa Byambaa, Anuurad Erdembileg, Wei Zhang, Chin-Shang Li, Robert Kaplan, Jason Lazar, Dan Merenstein, Roksana Karim, Brad Aouizerat, Mardge Cohen, Kenneth Butler, Savita Pahwa, Igho Ofotokun, Adaora A Adimora, Elizabeth Golub, Lars Berglund
OBJECTIVE: In the general population, lipoprotein(a) [Lp(a)] has been established as an independent causal risk factor for cardiovascular disease. Lp(a) levels are to a major extent regulated by a size polymorphism in the apolipoprotein(a) [apo(a)] gene. The roles of Lp(a)/apo(a) in human immunodeficiency virus (HIV)-related elevated cardiovascular disease risk remain unclear. APPROACH AND RESULTS: The associations between total plasma Lp(a) level, allele-specific apo(a) level, an Lp(a) level carried by individual apo(a) alleles, and common carotid artery intima-media thickness were assessed in 150 HIV-infected and 100 HIV-uninfected women in the WIHS (Women's Interagency HIV Study)...
March 23, 2017: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/28329334/turquoise-i-part-1b-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-with-ribavirin-for-hepatitis-c-virus-infection-in-hiv-1-coinfected-patients-on-darunavir
#4
David Wyles, Michael Saag, Rolando M Viani, Jacob Lalezari, Oluwatoyin Adeyemi, Laveeza Bhatti, Amit Khatri, Jennifer R King, Yiran B Hu, Roger Trinh, Nancy S Shulman, Peter Ruane
Background.: Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients. In healthy controls, coadministration of OBV/PTV/r + DSV + darunavir (DRV) lowered DRV trough concentration (Ctrough) levels. To assess the clinical significance of this change, TURQUOISE-I, Part 1b, evaluated the efficacy and safety of OBV/PTV/r + DSV + RBV in coinfected patients on stable, DRV-containing antiretroviral therapy (ART)...
March 14, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28329090/antiretrovirals-fractures-and-osteonecrosis-in-a-large-international-hiv-cohort
#5
Álvaro H Borges, Jennifer Hoy, Eric Florence, Dalibor Sedlacek, Hans-Jürgen Stellbrink, Vilma Uzdaviniene, Janez Tomazic, Panagiotis Gargalianos-Kakolyris, Patrick Schmid, Chloe Orkin, Court Pedersen, Clifford Leen, Christian Pradier, Fiona Mulcahy, Anna Lisa Ridolfo, Therese Staub, Fernando Maltez, Rainer Weber, Leo Flamholc, Galina Kyselyova, Jens D Lungren, Amanda Mocroft
Background: Antiretrovirals (ARVs) affect bone density and turnover, but their effect on risk of fractures and osteonecrosis of the femoral head is less understood. We investigated if exposure to ARVs increases the risk of both bone outcomes. Methods: EuroSIDA participants were followed to assess fractures and osteonecrosis. Poisson regression identified clinical, laboratory and demographic predictors of either bone outcome. Ever, current and cumulative exposures to ARVs were assessed...
February 22, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28328796/increased-incidence-of-cancer-observed-in-hiv-hcv-coinfected-patients-versus-hiv-monoinfected-1993-2014
#6
Héctor Meijide, Sonia Pértega, Iria Rodríguez-Osorio, Ángeles Castro-Iglesias, Josefa Baliñas, Guillermo Rodríguez-Martínez, Álvaro Mena, Eva Poveda
BACKGROUND: Cancer is a growing problem in persons living with HIV infection (PLWH) and hepatitis C virus (HCV) coinfection could play an additional role in carcinogenesis. Herein, all cancers in an HIV-mono and HIV/HCV-coinfected cohort were evaluated and compared to identify any differences between these two populations. METHODS: A retrospective cohort study was conducted including all cancers in PLWH between 1993 and 2014. Cancers were classified in two groups, AIDS-defining cancer (ADC) and non AIDS-defining cancer (NADC)...
March 21, 2017: AIDS
https://www.readbyqxmd.com/read/28328794/hcv-drives-increased-type-i-ifn-associated-impairments-associated-to-fibrosis-severity-in-art-treated-hiv-1-hcv-coinfected-individuals
#7
Morgane Griesbeck, Marc-Antoine Valantin, Karine Lacombe, Assia Samri-Hassimi, Julie Bottero, Catherine Blanc, Zineb Sbihi, Rima Zoorob, Christine Katlama, Marguerite Guiguet, Marcus Altfeld, Brigitte Autran
BACKGROUND: Viral coinfections might contribute to the increased immune activation and inflammation that persist in ART-treated HIV-1 patients. We investigated whether the HCV co-infection contributes to such alterations by impairing the pDC IFNα/TLR7 pathway in a highly homogeneous group of ART-treated HIV-1-HCV co-infected patients. METHODS: Twenty nine HIV-1-infected patients with fully suppressive ART were included, fifteen of whom being HCV co-infected with mild to moderate fibrosis and matched for their HIV-1 disease, and thirteen control healthy donors...
March 21, 2017: AIDS
https://www.readbyqxmd.com/read/28327813/relative-validity-of-a-food-frequency-questionnaire-in-patients-coinfected-with-hepatitis-c-virus-and-human-immunodeficiency-virus
#8
Anelise Fernanda Zanolla, Caroline Buss, Dimas Alexandre Kliemann, Giselle Souza Pinto, Vivian Silveira Vasques, Cristiane Valle Tovo
INTRODUCTION: Validation of food frequency questionnaires (FFQs) is recommended for accurate measurement of habitual food consumption. We assessed the relative validity of a FFQ in patients coinfected with hepatitis C virus and human immunodeficiency virus. METHODS: Each patient responded to a FFQ and three 24-hour food recalls. Pearson's correlation and weighted Kappa index analyses were performed to identify the FFQ relative validity and concordance. RESULTS: De-attenuated correlation coefficients ranged from 0...
January 2017: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/28323897/hcv-coinfection-contributes-to-hiv-pathogenesis-by-increasing-immune-exhaustion-in-cd8-t-cells
#9
Norma Rallón, Marcial García, Javier García-Samaniego, Noelia Rodríguez, Alfonso Cabello, Clara Restrepo, Beatriz Álvarez, Rosa García, Miguel Górgolas, José M Benito
BACKGROUND: There are several contributors to HIV-pathogenesis or insufficient control of the infection. However, whether HIV/HCV-coinfected population exhibits worst evolution of HIV-pathogenesis remains unclear. Recently, some markers of immune exhaustion have been proposed as preferentially upregulated on T-cells during HIV-infection. Herein, we have analyzed T-cell exhaustion together with several other contributors to HIV-pathogenesis that could be affected by HCV-coinfection. PATIENTS AND METHODS: Ninety-six patients with chronic HIV-infection (60 HIV-monoinfected and 36 HIV/HCV-coinfected), and 20 healthy controls were included in the study...
2017: PloS One
https://www.readbyqxmd.com/read/28321838/porphyria-cutanea-tarda-an-intriguing-genetic-disease-and-marker
#10
REVIEW
Nancy S Handler, Marc Z Handler, Matthew P Stephany, Glenn A Handler, Robert A Schwartz
Porphyrias are a group of intriguing genetic diseases of the heme pathway, of which porphyria cutanea tarda (PCT) is the most common. Resulting from a defect in enzymes in the porphyria pathway, PCT has been linked to several conditions. Recent studies have demonstrated a change in thinking regarding the human immunodeficiency virus (HIV) and development of PCT. The exacerbation of PCT with contraction of HIV is now believed to result from coinfection from the hepatitis C virus (HCV). Blistering of sun-exposed skin, a classic presenting sign of PCT, is not exclusive to the condition...
March 21, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28306597/diagnosis-of-viral-hepatitis
#11
Philippa J Easterbrook, Teri Roberts, Anita Sands, Rosanna Peeling
PURPOSE OF REVIEW: Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and HIV-HBV and HCV coinfection are major causes of chronic liver disease worldwide. Testing and diagnosis is the gateway for access to both treatment and prevention services, but there remains a large burden of undiagnosed infection globally. We review the global epidemiology, key challenges in the current hepatitis testing response, new tools to support the hepatitis global response (2016-2020 Global Hepatitis Health Sector strategy, and 2017 WHO guidelines on hepatitis testing and their key recommendations) and future directions and innovations in hepatitis diagnostics...
March 16, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28296739/ugt1a1-28-relationship-with-abnormal-total-bilirubin-levels-in-chronic-hepatitis-c-patients-outcomes-from-a-case-control-study
#12
Marcelo Moreira Tavares de Souza, Victor Van Vaisberg, Rodrigo Martins Abreu, Aline Siqueira Ferreira, Camila daSilvaFerreira, Paulo Dominguez Nasser, Helena Scavone Paschoale, Flair José Carrilho, Suzane Kioko Ono
Gilbert syndrome (GS) is a frequent benign clinical condition, marked by intermittent unconjugated hyperbilirubinemia, mostly due to the polymorphism uridine diphosphate-glucuronosyltransferase 1A1*28 (UGT1A1*28). Hyperbilirubinemia has been reported in a GS patient undergoing hepatitis C treatment, and other UGT isoforms polymorphisms have been linked to worse outcomes in viral hepatitis. Yet, little is known to GS contributions' to the liver disease scenario. Our aim was to assess UGT1A1 genotypes' frequency in chronic hepatitis C (CHC) patients and correlate with total bilirubin (TB)...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28294492/high-prevalence-of-willingness-to-use-direct-acting-antiviral-based-regimens-for-hepatitis-c-virus-hcv-infection-among-hiv-hcv-coinfected-people-who-use-drugs
#13
M E Socías, L Ti, H Dong, J Shoveller, T Kerr, J Montaner, M-J Milloy
OBJECTIVES: Despite the high burden of hepatitis C virus (HCV)-related morbidity and mortality among HIV-positive people who use illicit drugs (PWUD), uptake of interferon-based treatments for HCV infection has been negligible among this group. Direct-acting antiviral (DAA) therapies offer an opportunity to expand treatment access among this population. The aim of this study was to explore willingness to use DAA-based regimens among HIV/HCV-coinfected PWUD in Vancouver, Canada. METHODS: Data were drawn from the AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS), a prospective cohort of HIV-positive PWUD...
March 13, 2017: HIV Medicine
https://www.readbyqxmd.com/read/28282271/safety-and-efficacy-of-pegylated-interferon-lambda-ribavirin-and-daclatasvir-in-hcv-and-hiv-coinfected-patients
#14
Mark Nelson, Rafael Rubio, Adriano Lazzarin, Svetlana Romanova, Annie Luetkemeyer, Brian Conway, Jean-Michel Molina, Dong Xu, Subasree Srinivasan, Simon Portsmouth
To evaluate the efficacy and safety of pegylated interferon-lambda-1a (Lambda)/ribavirin (RBV)/daclatasvir (DCV) for treatment of patients coinfected with chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Treatment-naive patients were assigned to cohort A [HCV genotype (GT)-2 or -3] or cohort B [HCV GT-1(a or b) or -4]. All patients received Lambda/RBV/DCV for the first 12 weeks; cohort A received Lambda/RBV for an additional 12 weeks, followed by 24 weeks of follow-up, and cohort B received response-guided therapy...
March 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/28263458/perspectives-on-hcv-current-therapeutic-regimens-and-drug-drug-interactions
#15
Justin Chan, Raymond T Chung
Approximately 170 million people harbor chronic infection with hepatitis C virus (HCV) worldwide, with 3-4 million in the United States. As recently as 2013, the few treatment options available were poorly tolerated and only moderately effective. That changed when the first interferon-free direct-acting antiviral (DAA) regimen was US Food and Drug Administration-approved in December 2013. There are now 10 approved DAAs, with several more deep in the pipeline to approval. There are now interferon-free regimens available for every HCV genotype, and the application of DAA combination regimens has lifted response rates for historically difficult-to-treat patient groups to levels on par with more conventional treatment groups, including persons with HIV/HCV coinfection...
March 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28263457/ombitasvir-paritaprevir-ritonavir-and-dasabuvir-drug-interactions-with-antiretroviral-agents-and-drugs-forsubstance-abuse
#16
Jennifer R King, Rajeev M Menon
AbbVie's 3 direct-acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Safe and efficacious antiviral regimens resulting in minimal to no drug-drug interactions (DDIs) with antiretrovirals are needed to ensure that patients coinfected with HCV and the human immunodeficiency virus (HIV) achieve 12-week sustained virologic response rates similar to HCV-monoinfected patients...
March 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28263456/drug-drug-interactions-and-diagnostics-for-drug-users-with-hiv-and-hiv-hcv-coinfections-introduction
#17
Jag H Khalsa, Andrew H Talal, Gene Morse
Substance use and pharmacologic treatment of co-occurring infections such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are associated with many adverse consequences including pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs). The National Institute on Drug Abuse sponsored a 2-day conference on DDIs at which clinicians/scientists from government, academia, and the pharmaceutical industry presented the most current research findings to formulate a comprehensive overview of DDIs...
March 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28252531/evaluating-the-generalizability-of-clinical-trials-of-direct-acting-antivirals-for-hiv-hcv-coinfection
#18
Stacey C Tobin
No abstract text is available yet for this article.
March 1, 2017: AIDS
https://www.readbyqxmd.com/read/28248445/prevalence-and-distribution-of-hepatitis-c-virus-genotypes-in-spain-during-the-2000-2015-period-the-gehep-005-study
#19
Antonio Aguilera, Daniel Navarro, Francisco Rodríguez Frias, Isabel Viciana, Ana María Martínez-Sapiña, Mario José Rodríguez, Elisa Martró, María Del Carmen Lozano, Eleda Coletta, Laura Cardeñoso, Avelina Suárez, Matilde Trigo, Javier Rodríguez-Granjer, Natalia Montiel, Alberto de la Iglesia, Juan Carlos Alados, Cesar Vegas, Samuel Bernal, Felipe Fernández-Cuenca, María José Pena, Gabriel Reina, Silvia García-Bujalance, María Julia Echevarria, Laura Benítez, Sonia Pérez-Castro, Dolores Ocete, Isabel García-Arata, Carmen Guerrero, Manuel Rodríguez-Iglesias, Paz Casas, Federico García
AIM: We report the largest study on the prevalence and distribution of HCV genotypes in Spain (2000-2015), and we relate them with clinical, epidemiological and virological factors. METHODS: Patients from 29 hospitals in 10 autonomous communities (Andalusia, Aragon, Castilla-Leon, Catalonia, Galicia, Canary Islands, Madrid-Community, Valencian-Community, Murcia Region and Basque Country) have been studied. Annual distribution of HCV genotypes and subtypes, as well as gender, age, transmission route, HIV and/or HBV-coinfection, and treatment details were recorded...
March 1, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28240597/telaprevir-containing-triple-therapy-in-acute-hcv-coinfection-the-chat-study
#20
Christoph Boesecke, Gurmit K Jagjit Singh, Stefan H-A Scholten, Thomas Lutz, Axel Baumgarten, Stephan M Schneeweiss, Andreas Trein, Michael Rausch, Patrick Ingiliz, Jürgen K Rockstroh, Mark Nelson
BACKGROUND: No published randomised controlled data on the use of direct acting antivirals (DAA) in acute hepatitis C (AHC) coinfection exist. However, with the AHC epidemic ongoing among men who have sex with men (MSM) these are urgently needed. METHODS: The CHAT study is a randomised controlled trial of pegylated interferon + ribavirin (PR) plus telaprevir (TVR) for 12-24 weeks versus PR alone for 24-48 weeks in the response guided treatment of patients with AHC genotype (GT) 1 infection and HIV-1 co-infection in Germany and Great Britain...
February 27, 2017: Antiviral Therapy
keyword
keyword
62586
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"